

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary.)

Sheet 1 of 3

Complete if Known

Application Number	10/661,780
Filing Date	09/15/2003
First Named Inventor	PHILIPPE BOUCHARD
Art Unit	1614
Examiner Name	Brian Yong S. Kwon
Attorney Docket Number	098501-0305998

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial a reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with need communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <http://www.uspto.gov> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the grant of the Empor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.57 and 1.58. The information is required to obtain or retain a benefit by the public which is a file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.K./

PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/561,780
Filing Date	09/15/2003
First Named Inventor	PHILIPPE BOUCHARD
Art Unit	1614
Examiner Name	Brian Yong S. Kwon
Attorney Docket Number	098501-0305998

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		NESTOR, JR. ET AL., "Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity," J. Med. Chem., Institute of Bio-Organic Chemistry, Vol. 35 (No. 21), p. 3942-3948, (October 16, 1992).	
		DEGHENGI ET AL., "Antarelix (EP 24332) a novel water soluble LHRH antagonist," Biomed. Pharmacother., Europeptides (Argenteuil, France), Vol. 47 (No. 2-3), p. 107-110, (1993).	
		RIVIER ET AL., "Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6," J. Med. Chem., Salk Institute for Biological Studies (La Jolla, California), Vol. 35 (No. 23), p. 4270-4278, (November 13, 1992).	
	See Attachment 1	HAVIV ET AL., "In vitro and in vivo activities of reduced-size antagonists of luteinizing hormone-releasing hormone," J. Med. Chem., TAP Pharmaceuticals, Inc. (Abbott Park, IL), Vol. 37 (No. 5), p. 701-705, (March 4, 1994).	
		WEINBAUER ET AL., "Comparison of the antagonistic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis)," Andrologia, Institute of Reproductive Medicine of the University (Munster, Germany), Vol. 25 (No. 3), p. 141-147, (May-June 1993).	

Examiner Signature	/Brian-Yong Kwon/	Date Considered	02/15/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.K./

Addendum

Page 3 of 3

Attachment 1

- a.
- b. STOECKEMANN ET AL., "Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin or dimethylbenz[anthracene]-induced mammary carcinoma: studies with slow-release formulations," J. Cancer Res. Clin. Oncol., Hoechst AG, Pharma-Research (Frankfurt/Main, Germany), Vol. 119 (No. 8), p. 457-462, (1993).
- c.

/Brian-Yong Kwon/

02/15/2008

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.K./